CureFIP GS-441524 + Vitamin B12 is revolutionizing FIP treatments by combining GS-441524 antiviral therapy with Vitamin B12 injections
A needle length of 1 to 1.5 inches is generally recommended for adults
Localized Fat Reduction (Targeting Stubborn Fat Areas) Some research suggests that AOD-9604 may preferentially act on specific fat deposits, such as abdominal fat, making it a desirable option for body recomposition
Key metabolic effects include: Enhanced lipolysis through activation of fat breakdown pathways independent of growth hormone receptors Suppressed lipogenesis reducing conversion of non-fat substrates into stored fat Increased fat oxidation and energy expenditure in multiple species models No adverse effects on insulin sensitivity or glucose metabolism, unlike full-length growth hormone Independence from IGF-1 Signaling A critical distinction of AOD-9604 is its lack of IGF-1 pathway activation: No measurable changes in serum IGF-1 levels in human clinical trials Absence of growth-promoting effects on tissues No impact on blood glucose regulation or insulin resistance Avoidance of typical growth hormone side effects including edema and tissue overgrowth Metabolic Pathway Modulation Research indicates AOD-9604 influences energy metabolism through multiple mechanisms: Increased whole-body fat oxidation rates in animal models Enhanced metabolic rate without stimulant-like effects Potential modulation of uncoupling proteins in adipose tissue Effects on lipid metabolism that persist beyond plasma clearance Critical Mechanistic Gap: Despite extensive research, the primary receptor target for AOD-9604 remains unidentified
Oral Vitamin B12 may not provide adequate supplementation due to variations in metabolism and poor absorption
Deficiency symptoms in children include developmental delay, regression, irritability, involuntary movements, and hypotonia
